European Pharmaceutical Review Issue 4 2020
Posted: 25 August 2020 | European Pharmaceutical Review | No comments yet
Within this issue find articles on the complexities of sterility assurance, how to detect and eliminate the risk of NDMA contamination and the findings from a study involving a novel formulation of cannabinoids that has been developed to treat glioblastoma. Also included are articles on the opportunities blockchain provides for life science and healthcare businesses, as well as a discussion on how COVID-19 has impacted life sciences and biotech investment and its potential effect on investor behaviour as the pandemic subsides.


Find in the issue:
- REGULATORY INSIGHT
 The trials and tribulations of the medical devices and IVD regulations
 Paul Ranson, Morgan Lewis
- FORMULATION, DEVELOPMENT & DELIVERY
 Developing a preventive vaccine regimen to tackle Ebola
 Johan Van Hoof, Janssen Vaccines
 
- BIOPROCESSING & BIOPRODUCTION 
 Regenerative medicine: a manufacturing overview
 Maciej Nakoniecznik, University College London
 Overview of workflows and data approaches in bioproduction – an industry perspective
 Melanie Diefenbacher, Genedata
- MANUFACTURING, PACKAGING & LOGISTICS
 A glimpse at how Novartis’ manufacturing and supply organisation responded to COVID-19
 Steffen Lang, Novartis
 Beyond compliance: why embracing the FMD can transform medicine supply chain thinking
 Sébastien Sliski, Zetes
The rest of this content is restricted - login or subscribe free to access


Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- bi-monthly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here








